DK1353668T3 - Fremgangsmåder til fremstillingen af farmaceutiske sammensætninger, der indeholder epothilonanaloger, til behandlingen af cancer - Google Patents

Fremgangsmåder til fremstillingen af farmaceutiske sammensætninger, der indeholder epothilonanaloger, til behandlingen af cancer

Info

Publication number
DK1353668T3
DK1353668T3 DK02713446T DK02713446T DK1353668T3 DK 1353668 T3 DK1353668 T3 DK 1353668T3 DK 02713446 T DK02713446 T DK 02713446T DK 02713446 T DK02713446 T DK 02713446T DK 1353668 T3 DK1353668 T3 DK 1353668T3
Authority
DK
Denmark
Prior art keywords
cancer
preparation
treatment
methods
pharmaceutical compositions
Prior art date
Application number
DK02713446T
Other languages
English (en)
Inventor
Timothy M Malloy
Krishnaswamy Srinivas Raghavan
Sailesh Amilal Varia
Rebanta Bandyopadhyay
Andrea Panaggio
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28678063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1353668(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority claimed from PCT/US2002/001813 external-priority patent/WO2002058700A1/en
Application granted granted Critical
Publication of DK1353668T3 publication Critical patent/DK1353668T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK02713446T 2001-01-25 2002-01-22 Fremgangsmåder til fremstillingen af farmaceutiske sammensætninger, der indeholder epothilonanaloger, til behandlingen af cancer DK1353668T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000801P 2001-05-11 2001-05-11
PCT/US2002/001813 WO2002058700A1 (en) 2001-01-25 2002-01-22 Methods of administering epothilone analogs for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK1353668T3 true DK1353668T3 (da) 2008-06-30

Family

ID=28678063

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02713446T DK1353668T3 (da) 2001-01-25 2002-01-22 Fremgangsmåder til fremstillingen af farmaceutiske sammensætninger, der indeholder epothilonanaloger, til behandlingen af cancer

Country Status (25)

Country Link
US (1) US6670384B2 (da)
EP (2) EP1353668B1 (da)
KR (1) KR100851719B1 (da)
CN (1) CN100341505C (da)
AR (1) AR032409A1 (da)
AT (1) ATE389401T1 (da)
BG (1) BG66494B1 (da)
BR (1) BRPI0206509B8 (da)
CY (1) CY1108114T1 (da)
CZ (1) CZ20032021A3 (da)
DE (1) DE60225666T2 (da)
DK (1) DK1353668T3 (da)
EE (1) EE05301B1 (da)
ES (1) ES2304240T3 (da)
HK (2) HK1065946A1 (da)
HU (1) HU229349B1 (da)
IS (1) IS2865B (da)
NO (1) NO20130070L (da)
NZ (1) NZ526870A (da)
PE (1) PE20020734A1 (da)
PT (1) PT1353668E (da)
SK (1) SK288098B6 (da)
TW (1) TWI342211B (da)
UY (1) UY27137A1 (da)
YU (1) YU58203A (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
RU2003126171A (ru) * 2001-01-25 2005-02-27 Бристол-Маерс Сквибб Компани (Us) Парентеральный состав, содержащий аналоги эпотилона
MXPA03007394A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Tratamiento de tumores refractarios mediante uso de derivados de epotilona.
EP1383490B1 (en) * 2001-03-14 2012-04-25 Bristol-Myers Squibb Company Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130501A2 (en) 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
EP3566719A1 (en) 2010-05-18 2019-11-13 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
PL401116A1 (pl) * 2012-10-09 2014-04-14 Ryszka Florian Farmaceutyczny Zakład Naukowo-Produkcyjny Biochefa Kompozycja dodawana do płynów infuzyjnych
CN107041886A (zh) * 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
BR112022013685A2 (pt) 2020-01-10 2022-09-06 R Pharm Us Operating Llc Composições de ixabepilona
BR112023003572A2 (pt) * 2020-09-02 2023-04-04 Beijing Biostar Pharmaceuticals Co Ltd Formulação oral sólida de utidelona

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
CN1544436A (zh) 1997-02-25 2004-11-10 ���＼���о����޹�˾��GBF�� 3，7-保护的环氧噻嗪酮-n-氧化物及其制备方法
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
US6348551B1 (en) 1997-04-18 2002-02-19 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DK1001951T3 (da) 1997-07-16 2002-12-23 Schering Ag Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
NZ506389A (en) 1998-02-05 2003-07-25 Novartis Ag Pharmaceutical compositions containing epothilone which can be optionally lyophilised
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
CA2352505C (en) * 1998-12-22 2009-04-07 Novartis Ag Epothilone derivatives and their use as antitumor agents
PL349863A1 (en) 1999-02-18 2002-09-23 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
HUP0302726A3 (en) 2007-08-28
HUP0302726A2 (hu) 2003-11-28
KR20040048874A (ko) 2004-06-10
CZ20032021A3 (cs) 2004-05-12
US20020169190A1 (en) 2002-11-14
HK1116339A1 (en) 2008-12-19
EE200300320A (et) 2003-10-15
AR032409A1 (es) 2003-11-05
CN100341505C (zh) 2007-10-10
TWI342211B (en) 2011-05-21
HK1065946A1 (en) 2005-03-11
US6670384B2 (en) 2003-12-30
KR100851719B1 (ko) 2008-08-11
BRPI0206509B8 (pt) 2021-05-25
SK288098B6 (sk) 2013-07-02
EP1353668A1 (en) 2003-10-22
EP1938821A2 (en) 2008-07-02
UY27137A1 (es) 2002-08-30
EE05301B1 (et) 2010-06-15
HU229349B1 (en) 2013-11-28
CY1108114T1 (el) 2014-02-12
BG108112A (bg) 2004-11-30
NO20130070L (no) 2003-09-04
EP1938821A3 (en) 2009-02-18
ATE389401T1 (de) 2008-04-15
BRPI0206509A8 (pt) 2017-09-19
EP1938821B1 (en) 2016-03-30
IS2865B (is) 2014-02-15
CN1496258A (zh) 2004-05-12
NZ526870A (en) 2005-11-25
SK8562003A3 (en) 2004-07-07
IS6891A (is) 2003-07-24
DE60225666D1 (de) 2008-04-30
YU58203A (sh) 2006-08-17
BRPI0206509B1 (pt) 2018-10-02
BG66494B1 (bg) 2015-06-30
DE60225666T2 (de) 2009-04-16
PT1353668E (pt) 2008-06-30
ES2304240T3 (es) 2008-10-01
EP1353668B1 (en) 2008-03-19
PE20020734A1 (es) 2002-08-17
BR0206509A (pt) 2004-09-08

Similar Documents

Publication Publication Date Title
DK1353668T3 (da) Fremgangsmåder til fremstillingen af farmaceutiske sammensætninger, der indeholder epothilonanaloger, til behandlingen af cancer
DK1420759T3 (da) Farmaceutiske sammensætninger til behandling af astma
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
DK1196163T3 (da) Farmaceutiske sammensætninger til behandling af insulinresistens
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
DK1326585T4 (da) Fremgangsmåde til fremstilling af pulverformuleringer
DK1425001T3 (da) Phenethanolaminderivater til behandling af respiratoriske sygdomme
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
DK1656347T3 (da) Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
DK1450606T3 (da) Synergistiske sammensætninger til behandling af såsæd
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DK1601359T3 (da) Væskeformige, farmaceutiske formuleringer af palonosetron
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
DK1385826T3 (da) Fremgangsmåde til fremstilling af (S)-(+)- og (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azapin-5-carboxamid
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
FI20011889A (fi) Menetelmä ksylitolin valmistamiseksi
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1545634T3 (da) Fremgangsmåde til fremstilling af tørpulver-inhalationssammensætninger
DK2042182T3 (da) Farmaceutisk sammensætning, der omfatter arsen, til behandling af malignitet.
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater